Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.
Center for Diagnostic and Therapeutic Endoscopy, School of Medicine, Keio University, Tokyo, Japan.
Hepatol Commun. 2024 May 22;8(6). doi: 10.1097/HC9.0000000000000452. eCollection 2024 Jun 1.
The relationship between primary sclerosing cholangitis (PSC) and biliary bile acids (BAs) remains unclear. Although a few studies have compared PSC biliary BAs with other diseases, they did not exclude the influence of cholestasis, which affects the composition of BAs. We compared biliary BAs and microbiota among patients with PSC, controls without cholestasis, and controls with cholestasis, based on the hypothesis that alterations in BAs underlie the pathophysiology of PSC.
Bile samples were obtained using endoscopic retrograde cholangiopancreatography from patients with PSC (n = 14), non-hepato-pancreato-biliary patients without cholestasis (n = 15), and patients with cholestasis (n = 13).
The BA profiles showed that patients with PSC and cholestasis controls had significantly lower secondary BAs than non-cholestasis controls, as expected, whereas the ratio of cholic acid/chenodeoxycholic acid in patients with PSC was significantly lower despite cholestasis, and the ratio of (cholic acid + deoxycholic acid)/(chenodeoxycholic acid + lithocholic acid) in patients with PSC was significantly lower than that in the controls with or without cholestasis. The BA ratio in the bile of patients with PSC showed a similar trend in the serum. Moreover, there were correlations between the alteration of BAs and clinical data that differed from those of the cholestasis controls. Biliary microbiota did not differ among the groups.
Patients with PSC showed characteristic biliary and serum BA compositions that were different from those in other groups. These findings suggest that the BA synthesis system in patients with PSC differs from that in controls and patients with other cholestatic diseases. Our approach to assessing BAs provides insights into the pathophysiology of PSC.
原发性硬化性胆管炎(PSC)与胆汁酸(BAs)之间的关系尚不清楚。尽管一些研究比较了 PSC 胆汁 BAs 与其他疾病,但它们并未排除影响胆汁酸组成的胆汁淤积的影响。我们根据 BAs 改变是 PSC 病理生理学基础的假说,比较了 PSC 患者、无胆汁淤积的对照组和胆汁淤积对照组之间的胆汁 BAs 和微生物群。
通过内镜逆行胰胆管造影术从 PSC 患者(n=14)、无肝胰胆疾病且无胆汁淤积的对照组(n=15)和胆汁淤积的对照组(n=13)中获得胆汁样本。
BA 谱显示,PSC 患者和胆汁淤积对照组的次级 BAs 明显低于无胆汁淤积对照组,这是预期的结果,尽管存在胆汁淤积,但 PSC 患者的胆酸/鹅脱氧胆酸比值明显较低,PSC 患者的(胆酸+脱氧胆酸)/(鹅脱氧胆酸+石胆酸)比值明显低于有或无胆汁淤积的对照组。PSC 患者胆汁中的 BA 比值在血清中也呈现出类似的趋势。此外,BA 改变与临床数据之间存在相关性,与胆汁淤积对照组不同。各组之间胆汁微生物群没有差异。
PSC 患者表现出与其他组不同的特征性胆汁和血清 BA 组成。这些发现表明,PSC 患者的 BA 合成系统与对照组和其他胆汁淤积性疾病患者的不同。我们评估 BAs 的方法为 PSC 的病理生理学提供了新的见解。